Arthritis News and Research

Latest Arthritis News and Research

Santarus, Cosmo announce positive results from budesonide MMX Phase III study in ulcerative colitis

Santarus, Inc. and Cosmo Pharmaceuticals S.p.A. today announced positive top-line results from the Phase III clinical study conducted in the U.S. and India to evaluate the safety and efficacy of budesonide MMX® for the induction of remission of mild or moderate active ulcerative colitis. The study results show that budesonide MMX 9 mg taken once daily met the primary endpoint of superiority to placebo.

30 Sep 2010

Rigel earns $25M milestone payment from Astrazeneca for clinical development of fostamatinib

Rigel Pharmaceuticals, Inc. today announced that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones in the agreement the two companies have regarding the clinical development of fostamatinib (R788), a novel oral syk inhibitor. The first milestone is for initiation of the phase 3 clinical program with fostamatinib in patients with rheumatoid arthritis (RA) that was announced by AstraZeneca earlier today.

29 Sep 2010

XOMA completes patient enrollment in XOMA 052 Phase 2a trial

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that patient enrollment was recently completed for the company's Phase 2a trial of XOMA 052 in patients with Type 2 diabetes.

29 Sep 2010

Inefficiencies in treatment of chronic pain increases healthcare costs and prolongs patient suffering

A new report launched today in the European Parliament shows inefficiencies in the treatment of chronic pain result in increasing healthcare costs and prolonged patient suffering.

29 Sep 2010

Florida likely to seek waiver on medical loss ratio; Ariz. cuts back Medicaid benefits

The Hill Healthwatch: "Florida's 14-member insurance advisory board has unanimously passed a resolution to seek a waiver from the health law's medical loss ratio. An official with the Florida Office of Insurance Regulation tells The Hill that the board's vote means it's a 'done deal' that the state will formally seek some kind of waiver but the board is gathering public input through Oct. 8.

29 Sep 2010

Scientists use turmeric extract to target cancer cells

Scientists at the University of Leicester, funded by Hope Against Cancer, are pioneering the use of a common curry cooking ingredient to target cancer cells. The research in the University Department of Cancer Studies and Molecular Medicine is making use of actual tissue from tumours extracted from patients undergoing surgery.

29 Sep 2010

Combination therapy reduces radiographic evidence of joint destruction in rheumatoid arthritis: Study

A study conducted at Copenhagen University Hospital showed that treatment of rheumatoid arthritis (RA) with disease modifying antirheumatic drugs (DMARDs), glucocorticoids, biologic agents, or a combination of agents significantly reduced radiographic evidence of joint destruction, with a relative effect of 48%-72% as compared with placebo.

29 Sep 2010

Further trials needed to determine clinical application of Abatacept in SLE

Results from a 12-month multi-center clinical trial did not show therapeutic benefit of abatacept over placebo in patients with non-life threatening systemic lupus erythematosus (SLE). Abatacept failed to prevent new disease flares in SLE patients tapered from corticosteroids in an analysis where mild, moderate and severe disease flares were evaluated together. Full details of the phase IIb clinical trial are published in the October issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

29 Sep 2010

Researchers find genetic variants that cause arthritis in breast cancer patients taking aromatase inhibitors

Mayo Clinic researchers and their international colleagues have discovered genetic variants that lead to severe arthritis for a subset of women when taking aromatase inhibitors to treat their breast cancer. This serious side effect is so painful that many women halt their lifesaving medication. The findings appear today in the online issue of Journal of Clinical Oncology.

28 Sep 2010

Galapagos initiates phase II clinical study of GLPG0259 drug in RA patients

Galapagos NV announced today that it has started a Phase II clinical study for the Company's flagship program GLPG0259, a novel drug being developed for rheumatoid arthritis. In this clinical trial, the safety and efficacy of this novel candidate drug will be tested in RA patients. Galapagos plans to announce interim results by the middle of next year and complete the trial by the end of 2011.

28 Sep 2010

Bayer’s new oral contraceptive receives FDA approval

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved a new oral contraceptive, Beyaz (drospirenone / ethinyl estradiol / levomefolate calcium tablets and levomefolate calcium tablets).

28 Sep 2010

Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients

Chelsea Therapeutics International, Ltd. has initiated enrollment in a multinational, 12-week, double-blind Phase II trial designed to compare the efficacy and tolerability of CH-4051 against methotrexate (MTX) in 250 patients with rheumatoid arthritis (RA) who are experiencing an inadequate response to MTX treatment.

27 Sep 2010

REMURA Phase 2 clinical study results highlighted at Tear Film & Ocular Surface conference

ISTA Pharmaceuticals, Inc. today highlighted results from the Company's REMURA (bromfenac ophthalmic solution for dry eye) Phase 2 clinical study.

27 Sep 2010

Study finds increasing number of elderly people are prone to celiac diseases

Working to solve the puzzle of when people develop celiac disease has led researchers from the University of Maryland School of Medicine Center for Celiac Research to some surprising findings. They have found that the autoimmune disorder is on the rise with evidence of increasing cases in the elderly.

27 Sep 2010

Researchers identify cellular/molecular defect in T cell regulatory pathway

Researchers at Columbia University Medical Center have identified a defect in the T cell regulatory pathway which normally controls autoreactive T cells that attack the body's own tissues and organs. A majority of people with Type 1 diabetes who were tested in the study were found to have the newly-identified cellular/molecular defect, and the researchers were able to successfully correct the defect in-vitro.

27 Sep 2010

GBS pathogen suppresses immune cell function in newborn infants: Research

Group B Streptococcus (GBS), a bacterial pathogen that causes sepsis and meningitis in newborn infants, is able to shut down immune cell function in order to promote its own survival, according to researchers at the University of California, San Diego School of Medicine and the Skaggs School of Pharmacy and Pharmaceutical Sciences.

27 Sep 2010

Alzheimer's treatments may prove effective if started in middle-aged people: Study

Memory lapses that occur with normal aging are a source of worry for many who fear Alzheimer's disease. Now a new Mayo Clinic-led study published in the July 16 issue of the New England Journal of Medicine suggests that the carriers of a common genetic risk factor for Alzheimer's disease begin to have memory declines in their mid-50s, far earlier than previously thought.

27 Sep 2010

Calcitonin combination therapy may help treat osteoarthritis: Study

Tarsa Therapeutics, Inc. and Unigene Laboratories, Inc. today reported preclinical data showing that calcitonin may have synergistic effects in combination with other drugs in reducing the collagen degradation associated with osteoarthritis.

27 Sep 2010

Amgen announces voluntary recall of certain lots of EPOGEN and PROCRIT

Amgen announced today that certain lots of EPOGEN® and PROCRIT® (Epoetin alfa) vials are being voluntarily recalled from specialty distributors, wholesalers, pharmacies and healthcare providers as a precaution. The product that is being recalled may contain extremely thin glass flakes (lamellae) that are barely visible in most cases. The lamellae result from the interaction of the formulation with glass vials over the shelf life of the product.

24 Sep 2010

Team to identify safety risks with care in homes

Lawrence S. Bloomberg Faculty of Nursing professor, Dr. Diane Doran, was awarded more than $1 million for research that will help protect the safety of over 900,000 Canadians who receive health care services in their homes every day.

24 Sep 2010

Arthritis News and Research

Latest Arthritis News and Research

Santarus, Cosmo announce positive results from budesonide MMX Phase III study in ulcerative colitis

Rigel earns $25M milestone payment from Astrazeneca for clinical development of fostamatinib

XOMA completes patient enrollment in XOMA 052 Phase 2a trial

Inefficiencies in treatment of chronic pain increases healthcare costs and prolongs patient suffering

Florida likely to seek waiver on medical loss ratio; Ariz. cuts back Medicaid benefits

Scientists use turmeric extract to target cancer cells

Combination therapy reduces radiographic evidence of joint destruction in rheumatoid arthritis: Study

Further trials needed to determine clinical application of Abatacept in SLE

Researchers find genetic variants that cause arthritis in breast cancer patients taking aromatase inhibitors

Galapagos initiates phase II clinical study of GLPG0259 drug in RA patients

Bayer’s new oral contraceptive receives FDA approval

Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients

REMURA Phase 2 clinical study results highlighted at Tear Film & Ocular Surface conference

Study finds increasing number of elderly people are prone to celiac diseases

Researchers identify cellular/molecular defect in T cell regulatory pathway

GBS pathogen suppresses immune cell function in newborn infants: Research

Alzheimer's treatments may prove effective if started in middle-aged people: Study

Calcitonin combination therapy may help treat osteoarthritis: Study

Amgen announces voluntary recall of certain lots of EPOGEN and PROCRIT

Team to identify safety risks with care in homes

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Arthritis News and Research

Latest Arthritis News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in